Central Nervous System Pharmacology Practice Questions

Q: Pure opiate antagonists include all of the following except:

Nalorphine. ### Explanation The classification of opioid ligands is based on their intrinsic activity at opioid receptors (primarily $\mu$, $\kappa$, and $\delta$). **1. Why Nalorphine is the Correct Answer:** Nalorphine is a **mixed agonist-antagonist**, not a pure antagonist. It acts as a competitive antagonist at $\mu$ receptors (reversing morphine-induced respiratory depression) but behaves as a partial agonist at $\kappa$ receptors. Because it possesses intrinsic agonistic activity, it can induce dysphoria and mild analgesia, disqualifying it from being a "pure" antagonist. **2. Analysis of Incorrect Options (Pure Antagonists):** Pure antagonists have affinity for opioid receptors but zero intrinsic activity; they block the effects of both endogenous and exogenous opioids without producing any morphine-like effects. * **Naloxone:** The prototype pure antagonist. It is short-acting and administered parenterally for the acute reversal of opioid overdose. * **Naltrexone:** A long-acting pure antagonist with high oral bioavailability. It is primarily used for the maintenance of opioid-free states in addicts and for reducing alcohol cravings. * **Nalmefene:** A newer pure antagonist similar to naltrexone but with a longer half-life, used for treating opioid overdose and alcohol dependence. **3. NEET-PG High-Yield Clinical Pearls:** * **Naloxone** is the drug of choice for **Opioid Overdose** (Triad: Pinpoint pupil, Respiratory depression, Coma). * **Naltrexone** is FDA-approved for **Alcohol Dependence** (decreases the "reward" of drinking). * **Methylnaltrexone/Alvimopan:** These are peripheral $\mu$-antagonists used for **Opioid-Induced Constipation** (OIC) as they do not cross the blood-brain barrier. * **Nalorphine** is rarely used clinically today because its $\kappa$-agonism causes unpleasant side effects like hallucinations and anxiety.

Q: Which antiepileptic drug can lead to gingival hyperplasia?

Phenytoin. **Explanation:** **Phenytoin** is the correct answer. Gingival hyperplasia (overgrowth of the gums) is a classic, dose-independent side effect seen in approximately 50% of patients on long-term Phenytoin therapy. **Mechanism:** Phenytoin induces the proliferation of keratinocytes and fibroblasts. It also decreases the degradation of connective tissue by reducing the activity of collagenases and increasing the expression of Platelet-Derived Growth Factor (PDGF). This leads to an accumulation of extracellular matrix in the gingival tissues. Good oral hygiene can mitigate, but not always prevent, this condition. **Analysis of Incorrect Options:** * **B. Carbamazepine:** Primarily associated with diplopia, ataxia, and idiosyncratic reactions like SIADH (hyponatremia) and Stevens-Johnson Syndrome (SJS), especially in patients with the HLA-B*1502 allele. * **C. Valproate:** Common side effects include weight gain, alopecia (thinning of hair), hepatotoxicity, and pancreatitis. It is a known teratogen (neural tube defects). * **D. Lamotrigine:** Its most significant life-threatening side effect is a severe skin rash, which can progress to Stevens-Johnson Syndrome (SJS) or Toxic Epidermal Necrolysis (TEN). **High-Yield Clinical Pearls for NEET-PG:** * **Mnemonic for Phenytoin Side Effects (P-H-E-N-Y-T-O-I-N):** **P**-450 induction, **H**irsutism, **E**nlarged gums (Gingival Hyperplasia), **N**ystagmus, **Y**ellow-brown skin (pigmentation), **T**eratogenicity (Fetal Hydantoin Syndrome), **O**steomalacia (due to Vit D interference), **I**nterference with B12/Folate (Megaloblastic anemia), **N**europathy (Peripheral). * **Zero-order kinetics:** Phenytoin follows saturation kinetics at therapeutic concentrations, making its plasma levels unpredictable. * **Other drugs causing Gingival Hyperplasia:** Cyclosporine (immunosuppressant) and Nifedipine (Calcium Channel Blocker).

Q: Modafinil is used as an adjunct in the treatment of which condition?

Sleep apnea syndrome. **Explanation:** **Modafinil** is a non-amphetamine psychostimulant that promotes wakefulness. While it is a first-line treatment for Narcolepsy, the question asks for its use as an **adjunct**. **Why Option A is Correct:** In **Obstructive Sleep Apnea (OSA)**, the primary treatment is Continuous Positive Airway Pressure (CPAP). However, many patients continue to experience residual Excessive Daytime Sleepiness (EDS) despite effective CPAP therapy. Modafinil is FDA-approved and clinically used as an **adjunct** to CPAP to manage this persistent sleepiness. It does not treat the underlying airway obstruction but improves the patient's functional wakefulness. **Analysis of Incorrect Options:** * **B. Narcolepsy:** Modafinil is considered a **first-line monotherapy** (not typically labeled as an adjunct) for EDS associated with narcolepsy due to its lower abuse potential compared to amphetamines. * **C. ADHD:** While sometimes used "off-label" in adults who do not respond to stimulants, it is not a standard or primary adjunct treatment for ADHD. * **D. Shift Work Disorder:** Modafinil is a **primary treatment** indicated for patients with Shift Work Sleep Disorder to improve alertness during work hours; it is not used adjunctively here. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism of Action:** It inhibits the reuptake of Dopamine (DAT inhibitor) and increases levels of **Orexin/Hypocretin** and Histamine in the hypothalamus. * **Side Effects:** Most common is headache. Serious but rare: **Stevens-Johnson Syndrome (SJS)**. * **Advantage:** Unlike amphetamines, it has low peripheral sympathomimetic activity (less tachycardia/hypertension) and lower potential for addiction. * **Armodafinil:** The R-enantiomer of modafinil with a longer half-life.

Q: Which neurotransmitter is primarily responsible for the action of Barbiturates?

GABA. **Explanation:** **1. Why GABA is correct:** Barbiturates act as positive allosteric modulators of the **GABA-A receptor** complex. They bind to a specific site on the chloride channel, distinct from the benzodiazepine binding site. Their primary mechanism involves **increasing the duration** of chloride channel opening (mnemonic: *Barbi-DUR-ate* for duration). At higher concentrations, barbiturates can also act as **GABA-mimetics**, directly activating the receptor even in the absence of GABA, which contributes to their lower therapeutic index and higher risk of fatal overdose compared to benzodiazepines. **2. Why the other options are incorrect:** * **Glutamate & Aspartate:** These are the primary **excitatory** neurotransmitters in the CNS. While barbiturates do inhibit glutamate receptors (specifically AMPA receptors) at high doses, this is a secondary effect. Their sedative-hypnotic action is fundamentally mediated through GABA. * **Glycine:** This is the major inhibitory neurotransmitter in the **spinal cord** and brainstem. Barbiturates do not primarily target glycine receptors to exert their central sedative effects. **3. High-Yield Clinical Pearls for NEET-PG:** * **Mechanism Difference:** Benzodiazepines increase the **frequency** of channel opening, whereas Barbiturates increase the **duration**. * **Enzyme Induction:** Barbiturates are potent **CYP450 enzyme inducers**, leading to numerous drug interactions (e.g., decreasing the efficacy of Warfarin or Oral Contraceptives). * **Contraindication:** They are strictly contraindicated in **Acute Intermittent Porphyria** because they induce ALA synthase, the rate-limiting enzyme in porphyrin synthesis. * **Antidote:** Unlike benzodiazepines (Flumazenil), there is **no specific antidote** for barbiturate poisoning; management is purely supportive (alkalinization of urine for Phenobarbital).

Q: All of the following act through GABA except?

Carbamazepine. **Explanation:** The question tests the understanding of the mechanisms of action of various CNS drugs, specifically focusing on the GABAergic system. **Why Carbamazepine is the correct answer:** Carbamazepine is an anticonvulsant that primarily acts by **blocking voltage-gated sodium channels** in their inactivated state. This stabilizes neuronal membranes and inhibits repetitive firing. It does **not** have a direct or indirect effect on the GABA receptor complex. **Analysis of incorrect options:** * **Phenobarbitone:** This is a barbiturate that acts as a positive allosteric modulator of the **GABA-A receptor**. It increases the **duration** of chloride channel opening and, at higher doses, can directly mimic GABA (GABA-mimetic). * **Zopiclone:** This is a "Z-drug" (non-benzodiazepine hypnotic). It acts selectively on the **α1 subunit of the GABA-A receptor** to enhance the inhibitory effects of GABA, similar to benzodiazepines but with a different chemical structure. * **Muscimol:** This is a potent, selective **GABA-A receptor agonist** derived from the mushroom *Amanita muscaria*. It binds directly to the same site as the endogenous neurotransmitter GABA. **High-Yield Clinical Pearls for NEET-PG:** * **Barbiturates vs. Benzodiazepines:** Barbiturates increase the *duration* of Cl- channel opening, while Benzodiazepines increase the *frequency* (Mnemonic: **Ben**zodiazepines = **Fr**equency; **Bar**biturates = **Dur**ation). * **Carbamazepine** is the drug of choice for **Trigeminal Neuralgia**. * **Zopiclone/Zolpidem** are preferred for insomnia because they cause less disruption of sleep architecture and have a lower potential for dependence compared to benzodiazepines. * **GABA-B Agonist:** Remember that **Baclofen** acts on GABA-B receptors (G-protein coupled) to treat spasticity.

Q: Which of the following is an antagonist of benzodiazepines?

Flumazenil. ### Explanation **Correct Option: D. Flumazenil** Flumazenil is a competitive antagonist at the **GABA-A receptor** benzodiazepine (BZD) binding site. It specifically reverses the sedative, psychomotor, and anticonvulsant effects of benzodiazepines and "Z-drugs" (Zolpidem, Zopiclone). It is the drug of choice for managing BZD overdose and reversing anesthesia induced by midazolam. **Analysis of Incorrect Options:** * **A. Nalorphine:** This is a mixed opioid agonist-antagonist. While it can antagonize opioid effects, it is rarely used today due to its psychotomimetic side effects. * **B. Carbamazepine:** This is an anticonvulsant and mood stabilizer that works primarily by blocking **voltage-gated sodium channels**. It has no antagonistic activity at the BZD receptor. * **C. Naloxone:** This is a pure **opioid receptor antagonist**. It is the specific antidote for opioid overdose (e.g., morphine, heroin) but has no effect on BZD-induced respiratory depression. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism:** Flumazenil has a high affinity for the BZD site but lacks intrinsic activity (neutral antagonist). * **Duration of Action:** Flumazenil has a very **short half-life** (~1 hour). Since most BZDs (like Diazepam) last longer, "re-sedation" can occur, necessitating repeated doses or an infusion. * **Contraindication:** Avoid flumazenil in patients with long-term BZD dependence or those who have co-ingested TCAs, as it can precipitate **acute withdrawal seizures**. * **Z-drugs:** Remember that Flumazenil also reverses non-benzodiazepine hypnotics like **Zolpidem and Zaleplon**.

Q: Which antiepileptic drug can cause folate deficiency anemia?

Phenytoin. **Explanation:** **Phenytoin** is the correct answer because it is a well-known inducer of **folate deficiency**, which can lead to **megaloblastic anemia**. The underlying mechanism involves Phenytoin’s ability to interfere with the intestinal absorption of dietary folates and increase the hepatic metabolism of folate by inducing microsomal enzymes. Chronic use leads to depleted folate stores, resulting in impaired DNA synthesis in red blood cell precursors. **Analysis of Options:** * **Valproate (A):** While Valproate is associated with bone marrow suppression (thrombocytopenia) and is highly teratogenic (neural tube defects due to folate interference in pregnancy), it is not the classic cause of megaloblastic anemia in routine clinical practice compared to Phenytoin. * **Phenobarbitone (C) & Carbamazepine (D):** Both are enzyme inducers and can occasionally lower folate levels, but they are significantly less likely to cause clinically symptomatic megaloblastic anemia than Phenytoin. **High-Yield Clinical Pearls for NEET-PG:** * **Mnemonic for Phenytoin Side Effects (PHENYTOIN):** **P**-P450 induction, **H**-Hirsutism, **E**-Enlarged gums (Gingival hyperplasia), **N**-Nystagmus, **Y**-Yellow-brown skin (pigmentation), **T**-Teratogenicity (Fetal Hydantoin Syndrome), **O**-Osteomalacia (Vitamin D interference), **I**-Interference with B9 (Megaloblastic Anemia), **N**-Neuropathy. * **Management:** Patients on long-term Phenytoin therapy should be monitored for macrocytosis and often require supplemental **Folic Acid**. * **Gum Hyperplasia:** This occurs due to increased expression of Platelet-Derived Growth Factor (PDGF).

Q: Which of the following agents enhances the bioavailability of levodopa in patients with Parkinson's disease?

Entacapone. **Explanation:** The correct answer is **Entacapone**. **Why Entacapone is correct:** Levodopa is the precursor to dopamine. When administered orally, it is rapidly metabolized in the periphery by two enzymes: **DOPA decarboxylase (DDC)** and **Catechol-O-methyltransferase (COMT)**. While Carbidopa inhibits DDC, it leads to a compensatory increase in COMT activity, which converts levodopa into 3-O-methyldopa. **Entacapone** is a selective, reversible **peripheral COMT inhibitor**. By blocking this pathway, it prevents the peripheral degradation of levodopa, thereby increasing its plasma half-life and **bioavailability** to the brain. This helps reduce "off" periods in patients with motor fluctuations. **Why the other options are incorrect:** * **Amantadine (A):** An antiviral drug that acts by increasing dopamine release and blocking NMDA receptors. It does not affect levodopa metabolism. * **Ropinirole (B):** A non-ergot **Dopamine Agonist** that acts directly on postsynaptic D2/D3 receptors. It mimics dopamine but does not alter levodopa levels. * **Selegiline (D):** A selective **MAO-B inhibitor**. It acts primarily within the **Central Nervous System** to prevent the breakdown of dopamine already formed in the brain. It does not significantly enhance the peripheral bioavailability of levodopa. **High-Yield Clinical Pearls for NEET-PG:** * **Tolcapone vs. Entacapone:** Entacapone acts only peripherally, whereas Tolcapone acts both peripherally and centrally. However, Tolcapone is rarely used due to **hepatotoxicity** (requires LFT monitoring). * **Orange Discoloration:** Entacapone can cause harmless orange discoloration of urine. * **Stalevo:** A fixed-dose combination of Levodopa + Carbidopa + Entacapone.

Q: Which of the following drugs is known to cause aplastic anemia as a side effect?

Carbamazepine. **Explanation:** **Carbamazepine** is a first-line antiepileptic drug for focal seizures and trigeminal neuralgia [1]. Its association with **aplastic anemia** and agranulocytosis is a classic, high-yield side effect. While rare (occurring in approximately 2–5 per million patients per year), it is a serious idiosyncratic reaction involving bone marrow suppression. This necessitates baseline and periodic complete blood counts (CBC) during treatment. **Analysis of Incorrect Options:** * **A. Valproate:** Most commonly associated with **hepatotoxicity** (especially in children <2 years), weight gain, alopecia, and **thrombocytopenia** (low platelets), rather than global aplastic anemia. It is also highly teratogenic (neural tube defects). * **C. Lamotrigine:** The most significant life-threatening side effect is **Stevens-Johnson Syndrome (SJS)** or Toxic Epidermal Necrolysis (TEN). It does not typically cause bone marrow failure. * **D. Lithium:** Known for causing **leukocytosis** (an increase in white blood cell count), which is sometimes used therapeutically in Felty’s syndrome. Other side effects include nephrogenic diabetes insipidus, tremors, and hypothyroidism. **Clinical Pearls for NEET-PG:** * **HLA-B*1502 Link:** In patients of Asian descent, this allele significantly increases the risk of SJS/TEN when taking Carbamazepine. * **Enzyme Induction:** Carbamazepine is a potent **CYP450 inducer**, leading to many drug-drug interactions (e.g., decreasing the efficacy of oral contraceptives). * **Other drugs causing Aplastic Anemia:** Chloramphenicol, Phenylbutazone, Gold salts, and Felbamate [2].

Q: Which drug is used for smoking cessation?

Varenicline. **Explanation:** **Varenicline** is the correct answer. It is a **selective partial agonist at the α4β2 nicotinic acetylcholine receptors (nAChR)** in the brain. Its mechanism of action is twofold: 1. **Agonist Effect:** It provides a low-level release of dopamine, which helps mitigate the symptoms of nicotine withdrawal. 2. **Antagonist Effect:** By binding to the receptor with high affinity, it prevents inhaled nicotine from binding. This reduces the "reward" or reinforcement associated with smoking, making a relapse less satisfying. **Analysis of Incorrect Options:** * **Theophylline (Option A):** A methylxanthine used as a bronchodilator in asthma and COPD. It acts primarily by inhibiting phosphodiesterase (PDE) and antagonizing adenosine receptors. * **Bicalutamide (Option B):** A non-steroidal anti-androgen used in the management of prostate cancer. * **Salmeterol (Option C):** A Long-Acting Beta-2 Agonist (LABA) used for the maintenance treatment of asthma and COPD; it has no role in addiction medicine. **High-Yield Clinical Pearls for NEET-PG:** * **First-line agents** for smoking cessation include Varenicline, Bupropion (an atypical antidepressant), and Nicotine Replacement Therapy (NRT). * **Varenicline Side Effects:** The most common side effect is **nausea**. It is also associated with **neuropsychiatric symptoms** (vivid dreams, depression, suicidal ideation) and should be used cautiously in patients with pre-existing psychiatric illness. * **Bupropion** is specifically preferred in smokers who are concerned about weight gain or have comorbid depression, but it is contraindicated in patients with a history of seizures.

Question 1

Pure opiate antagonists include all of the following except:

Accepted Answer

Nalorphine

Answer

Naloxone

Answer

Nalmefene

Answer

Naltrexone

Question 2

Which antiepileptic drug can lead to gingival hyperplasia?

Accepted Answer

Phenytoin

Answer

Carbamazepine

Answer

Valproate

Answer

Lamotrigine

Question 3

Modafinil is used as an adjunct in the treatment of which condition?

Accepted Answer

Sleep apnea syndrome

Answer

Narcolepsy

Answer

Attention Deficit Hyperactivity Disorder (ADHD)

Answer

Shift work disorder

Question 4

Which neurotransmitter is primarily responsible for the action of Barbiturates?

Accepted Answer

GABA

Answer

Glutamate

Answer

Glycine

Answer

Aspartate

Question 5

All of the following act through GABA except?

Accepted Answer

Carbamazepine

Answer

Phenobarbitone

Answer

Zopiclone

Answer

Muscimol

Question 6

Which of the following is an antagonist of benzodiazepines?

Accepted Answer

Flumazenil

Answer

Nalorphine

Answer

Carbamazepine

Answer

Naloxone

Question 7

Which antiepileptic drug can cause folate deficiency anemia?

Accepted Answer

Phenytoin

Answer

Valproate

Answer

Phenobarbitone

Answer

Carbamazepine

Question 8

Which of the following agents enhances the bioavailability of levodopa in patients with Parkinson's disease?

Accepted Answer

Entacapone

Answer

Amantadine

Answer

Ropinirole

Answer

Selegiline

Question 9

Which of the following drugs is known to cause aplastic anemia as a side effect?

Accepted Answer

Carbamazepine

Answer

Valproate

Answer

Lamotrigine

Answer

Lithium

Question 10

Which drug is used for smoking cessation?

Accepted Answer

Varenicline

Answer

Theophylline

Answer

Biclutamide

Answer

Salmeterol

Central Nervous System Pharmacology — MCQs

Central Nervous System Pharmacology — MCQs

On this page

Practice by Chapter

Want unlimited practice?